The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
Open accessAbstract
INTRODUCTION In the randomized KEYNOTE-407 study (ClinicalTrials.gov, NCT02775435), pembrolizumab plus carboplatin and paclitaxel/nab-paclitaxel (chemotherapy) significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo plus chemotherapy in patients with previously untreated metastatic squamous non-small-cell lung cancer (NSCLC). We report updated efficacy outcomes from the protocol-specified final analysis and, for the first time, progression on next-line of treatment. METHODS Eligible patients were randomized to chemotherapy plus either pembrolizumab (n=278) or placebo (n=281). After positive results from the second interim analysis, patients still receiving placebo could crossover to pembrolizumab monotherapy at time of confirmed progressive disease. Primary endpoints were OS and PFS. PFS-2 (time from randomization to progression on next-line treatment/death, whichever occurred first) was an exploratory endpoint. RESULTS After median (range) follow-up of 14.3 (0.1-31.3) months, pembrolizumab plus chemotherapy continued to demonstrate a clinically meaningful improvement over placebo plus chemotherapy in OS (median [95%CI], 17.1 [14.4‒19.9] versus 11.6 [10.1‒13.7] months; hazard ratio [HR (95%CI)], 0.71 [0.58‒0.88]) and PFS (median, 8.0 [6.3‒8.4] versus 5.1 [4.3‒6.0] months; HR [95%CI], 0.57 [0.47‒0.69]). PFS-2 was longer for patients randomized to first-line pembrolizumab plus chemotherapy (HR [95% CI], 0.59 [0.49‒0.72]). Grade 3‒5 adverse events occurred in 74.1% and 69.6% of patients receiving pembrolizumab plus chemotherapy and placebo plus chemotherapy, respectively. CONCLUSION Pembrolizumab plus chemotherapy continued to demonstrate substantially improved OS and PFS in patients with metastatic squamous NSCLC. The PFS-2 outcomes support pembrolizumab plus chemotherapy as a standard first-line treatment in patients with metastatic squamous NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationPembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
Self-citationMok, T. S. K., Wu, Y.-L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,303
Self-citationReck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670
Self-citationBracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 756
Self-citationThatcher, N., Hirsch, F. R., Luft, A. V., Szczesna, A., Ciuleanu, T. E., Dediu, M., Ramlau, R., Galiulin, R. K., Bálint, B., Losonczy, G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00021-2 · Cited by 479
Self-citationMolecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
Hato, S. V., Khong, A., de Vries, I. J. M., & Lesterhuis, W. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3141 · Cited by 451
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
Apetoh, L., Ladoire, S., Coukos, G., & Ghiringhelli, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv209 · Cited by 280
Jotte, R. M., Cappuzzo, F., Vynnychenko, I., Stroyakovskiy, D., Rodriguez Abreu, D., Hussein, M. A., Soo, R. A., Conter, H. J., Kozuki, T., Silva, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.18_suppl.lba9000 · Cited by 219
Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells
Wang, Z., Till, B. G., & Gao, Q. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1331807 · Cited by 148
Latimer, N. R., Abrams, K. R., Lambert, P. C., Crowther, M. J., Wailoo, A., Morden, J. P., Akehurst, R. L., & Campbell, M. J. (2014) · Medical Decision Making · doi:10.1177/0272989x13520192 · Cited by 108
Latimer, N. R., Abrams, K. R., Lambert, P. C., Crowther, M. J., Wailoo, A., Morden, J. P., Akehurst, R., & Campbell, M. J. (2014) · Statistical Methods in Medical Research · doi:10.1177/0962280214557578 · Cited by 102
Kersten, K., Salvagno, C., & de Visser, K. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00516 · Cited by 95
Davies, J., Patel, M. I., Gridelli, C., de Marinis, F., Waterkamp, D., & McCusker, M. E. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175679 · Cited by 91
Matulonis, U. A., Oza, A. M., Ho, T. W., & Ledermann, J. A. (2014) · Cancer · doi:10.1002/cncr.29082 · Cited by 87
Paz-Ares, L. G., Ciuleanu, T., Yu, X., Salman, P., Płużański, A., Nagrial, A. M., Havel, L., Kowalyszyn, R. D., Audigier-Valette, C., Wu, Y.-L. L. C., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz453.004 · Cited by 48
Self-citationScarpace, S. L. (2015) · Drugs in Context · doi:10.7573/dic.212289 · Cited by 46
Jotte, R. M., Cappuzzo, F., Vynnychenko, I. O., Stroyakovskiy, D., Rodríguez‐Abreu, D., Hussein, M., Soo, R. A., Conter, H. J., Kozuki, T., Huang, K., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.484 · Cited by 20
Cited by
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00174 · Cited by 1,159
Self-citationToward personalized treatment approaches for non-small-cell lung cancer
Wang, M., Herbst, R. S., & Boshoff, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01450-2 · Cited by 1,093
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S. Y.-S., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00152-2 · Cited by 643
Self-citationHendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 620
Metadata
- Authors
- Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J., Hermes, B., Cicin, I., Medgyasszay, B., Rodríguez-Cid, J., Okamoto, I., Lee, S., Ramlau, R., Vladimirov, V., Cheng, Y., Deng, X., Zhang, Y., Bas, T., Piperdi, B., & Halmos, B.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 15
- Issue
- 10
- Pages
- 1657-1669
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W3037506839
- Cited by
- 631
- References
- 20
- FWCI
- 51.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.